Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Catalyst Pharmaceuticals Inc

3 Mid-Cap Stocks Analysts Believe Will Soar 50% or More

The blend of growth potential and stability in mid-cap pharma stocks is driven by rising demand for innovative therapies, strong economic conditions, and technological advancements that boost the sector's growth trajectory. Therefore, considering strong mid-cap stocks like Amphastar Pharmaceuticals (AMPH), Catalyst Pharmaceuticals (CPRX), and ACADIA Pharmaceuticals (ACAD), expected to soar…

StockNews.com

3 Small-Cap Healthcare Stocks Wall Street Loves

The healthcare industry is expected to witness robust growth driven by increased demand for medicines. Therefore, small-cap Wall Street healthcare favorites Amphastar Pharmaceuticals (AMPH), Catalyst Pharmaceuticals (CPRX), and Equillium (EQ) might be ideal additions to your portfolio. Keep reading….

StockNews.com

September Buy, Sell or Hold for This Pharma Sock: Catalyst Pharmaceuticals (CPRX)

Catalyst Pharmaceuticals (CPRX) delivered a robust performance in its last reported quarter. So, is now the right entry point in the stock? Let’s look at its financial metrics to gauge its prospects.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Pharma Stocks to Watch for Value in September

The pharmaceutical industry enjoys robust demand irrespective of economic cycles. Also, given its solid growth prospects, I think pharma stocks Pfizer (PFE), Catalyst Pharmaceuticals (CPRX), and Kiniksa Pharmaceuticals (KNSA) might be worth adding to one’s watchlist for value. Read on.

StockNews.com

3 Value Pharma Stocks to Keep Watching

The pharma industry’s ability to remain resilient in times of economic uncertainty offers an appealing investment opportunity. Hence, fundamentally sound pharma stocks Catalyst Pharmaceuticals (CPRX), MorphoSys (MOR), and Voyager Therapeutics (VYGR), which seem relatively undervalued to their peers, might be ideal additions to one’s watchlist. Read on.

StockNews.com

Which is the Better Value Stock for August: Catalyst Pharmaceuticals, Inc. (CPRX) vs. Teva Pharmaceutical Industries (TEVA)?

Fueled by steady demand, the pharmaceutical sector has shown resilience and expansion even in an uncertain economic environment. Amid this scenario, Catalyst Pharmaceuticals (CPRX) and Teva Pharmaceuticals (TEVA) are set to reap the rewards. However, which of the two is the better value stock for August? Read more to find…

StockNews.com

Is Catalyst Pharmaceuticals (CPRX) a Buy in the Near Future?

Catalyst Pharmaceuticals (CPRX) witnessed significant bottom-line growth in the first quarter but missed expectations. Does the biopharmaceutical company deserve a place in your portfolio in the near future? Let’s look at its financial metrics to get an idea….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

AbbVie (ABBV) and Catalyst Pharmaceuticals (CPRX): Analyzing Investment Potential

The pharmaceutical industry’s inelastic demand for its products helps it to weather economic downturns. With fears of an impending recession playing on the minds of investors, it could be wise to buy fundamentally strong pharmaceutical stock AbbVie (ABBV). On the other hand, given its mixed fundamentals and profitability, it could…

StockNews.com

5 Best Pharma Stocks to Buy Right Now

The pharma industry has experienced tremendous growth in recent years and should continue to grow amid the integration of advanced technologies. Hence, pharma stocks Eli Lilly (LLY), Takeda Pharmaceutical (TAK), Catalyst Pharmaceuticals (CPRX), Poseida Therapeutics (PSTX), and Voyager Therapeutics (VYGR) might be worth buying right now. Read on.

StockNews.com

5 Buy-Rated Healthcare Stocks Trading at a Discount

Inelastic demand, growing investments, and impressive breakthroughs should help the healthcare sector survive the potential recession. This is why we believe quality healthcare stocks Assertio (ASRT), Bayer (BAYRY), Bristol-Myers Squibb (BMY), Catalyst Pharmaceuticals (CPRX), and Ipsen (IPSEY), which are currently trading at discounts to their peers, could be solid investments…

StockNews.com

3 Top Value Stocks Perfect for a Volatile Market

The Fed’s hawkish stance to fight inflation is raising recession concerns. And analysts are becoming increasingly bearish on the near-term prospects. So, we think top-rated value stocks ARC Document (ARC), Assertio (ASRT), and Catalyst Pharmaceuticals (CPRX) could be solid picks to navigate a volatile environment. These stocks are rated Strong…

StockNews.com

5 "Strong Buy" Pharmaceutical Stocks to Own for the Long Haul

The inelastic demand and rising investments in research and development should drive the pharmaceutical industry’s growth in the long run. Therefore, pharmaceutical stocks AbbVie (ABBV), Amgen (AMGN), Catalyst (CPRX), Novo Nordisk (NVO), and Vertex (VRTX), which possess sound fundamentals, could be solid long-term investments. These stocks are rated Strong Buy…

StockNews.com

3 Pharmaceutical Stocks That Look Like Huge Bargains

Increasing investments in R&D and rising expenditure on healthcare are expected to bolster the pharmaceutical sector's growth. Therefore, we think the stocks of fundamentally sound pharmaceutical companies Bristol-Myers Squibb (BMY), Bayer Aktiengesellschaft (BAYRY), and Catalyst Pharmaceuticals, Inc. (CPRX), which are currently trading at huge discounts to their peers, could be…

StockNews.com

5 Pharmaceutical Stocks Under $10 to Buy Right Now

Supportive federal policies to boost medical research and development, tech integration, and robust demand are factors that are expected to drive the long-term growth of the pharmaceutical industry. Thus, we think it could be wise to bet on quality pharmaceutical stocks Catalyst Pharmaceuticals (CPRX), Radius Health (RDUS), Assertio Holdings (ASRT),…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Piper Sandler Increases Catalyst Pharma's Price Target Slightly After Q4 Earnings

Piper Sandler raised the price target marginally on Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) to $8.75 from $8.00, with an Overweight rating unchanged. Catalyst expects FY22 revenue of $195 million - $205 million, driven by transitioning ~125 patients previously on Ruzurgi onto Firdapse, analyst Joseph Catanzaro writes in a research note. Wall Street's estimate for sales…

Benzinga

Catalyst Pharma Expects FY22 Revenue Beat Consensus On Continued Recovery In Macroeconomic, Healthcare Activity

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) anticipates

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

BristolMyers Squibb Company

92 stories

Medical – Pharmaceuticals

Vertex Pharmaceuticals Incorporated

61 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.